How to obtain the image-derived blood concentration from ⁸⁹Zr-immuno-PET scans.

IF 3 2区医学 Q2 RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING

EJNMMI Physics Pub Date : 2024-02-07 DOI:10.1186/s40658-024-00621-7

Jessica E Wijngaarden, Amina Ahbari, Johanna E E Pouw, Henri N J M Greuter, Idris Bahce, Gerben J C Zwezerijnen, Daniëlle J Vugts, Guus A M S van Dongen, Ronald Boellaard, C Willemien Menke-van der Houven van Oordt, Marc C Huisman

{"title":"How to obtain the image-derived blood concentration from 89Zr-immuno-PET scans.","authors":"Jessica E Wijngaarden, Amina Ahbari, Johanna E E Pouw, Henri N J M Greuter, Idris Bahce, Gerben J C Zwezerijnen, Daniëlle J Vugts, Guus A M S van Dongen, Ronald Boellaard, C Willemien Menke-van der Houven van Oordt, Marc C Huisman","doi":"10.1186/s40658-024-00621-7","DOIUrl":null,"url":null,"abstract":"Background: PET scans using zirconium-89 labelled monoclonal antibodies (89Zr-mAbs), known as 89Zr-immuno-PET, are made to measure uptake in tumour and organ tissue. Uptake is related to the supply of 89Zr-mAbs in the blood. Measuring activity concentrations in blood, however, requires invasive blood sampling. This study aims to identify the best delineation strategy to obtain the image-derived blood concentration (IDBC) from 89Zr-immuno-PET scans.Methods: PET imaging and blood sampling of two 89Zr-mAbs were included, 89Zr-cetuximab and 89Zr-durvalumab. For seven patients receiving 89Zr-cetuximab, PET scans on 1-2 h, 2 and 6 days post-injection (p.i.) were analysed. Five patients received three injections of 89Zr-durvalumab. The scanning protocol for the first two injections consisted of PET scanning on 2, 5 and 7 days p.i. and for the third injection only on 7 days p.i. Blood samples were drawn with every PET scan and the sample-derived blood concentration (SDBC) was used as gold standard for the IDBC. According to an in-house developed standard operating procedure, the aortic arch, ascending aorta, descending aorta and left ventricle were delineated. Bland-Altman analyses were performed to assess the bias (mean difference) and variability (1.96 times the standard deviation of the differences) between IDBC and SDBC.Results: Overall, the activity concentration obtained from the IDBC was lower than from the SDBC. When comparing IDBC with SDBC, variability was smallest for the ascending aorta (20.3% and 17.0% for 89Zr-cetuximab and 89Zr-durvalumab, respectively). Variability for the other regions ranged between 17.9 and 30.8%. Bias for the ascending aorta was - 10.9% and - 11.4% for 89Zr-cetuximab and 89Zr-durvalumab, respectively.Conclusions: Image-derived blood concentrations should be obtained from delineating the ascending aorta in 89Zr-immuno-PET scans, as this results in the lowest variability with respect to sample-derived blood concentrations.","PeriodicalId":11559,"journal":{"name":"EJNMMI Physics","volume":"11 1","pages":"16"},"PeriodicalIF":3.0000,"publicationDate":"2024-02-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10847076/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"EJNMMI Physics","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1186/s40658-024-00621-7","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING","Score":null,"Total":0}

引用次数: 0

Abstract

Background: PET scans using zirconium-89 labelled monoclonal antibodies (⁸⁹Zr-mAbs), known as ⁸⁹Zr-immuno-PET, are made to measure uptake in tumour and organ tissue. Uptake is related to the supply of ⁸⁹Zr-mAbs in the blood. Measuring activity concentrations in blood, however, requires invasive blood sampling. This study aims to identify the best delineation strategy to obtain the image-derived blood concentration (IDBC) from ⁸⁹Zr-immuno-PET scans.

Methods: PET imaging and blood sampling of two ⁸⁹Zr-mAbs were included, ⁸⁹Zr-cetuximab and ⁸⁹Zr-durvalumab. For seven patients receiving ⁸⁹Zr-cetuximab, PET scans on 1-2 h, 2 and 6 days post-injection (p.i.) were analysed. Five patients received three injections of ⁸⁹Zr-durvalumab. The scanning protocol for the first two injections consisted of PET scanning on 2, 5 and 7 days p.i. and for the third injection only on 7 days p.i. Blood samples were drawn with every PET scan and the sample-derived blood concentration (SDBC) was used as gold standard for the IDBC. According to an in-house developed standard operating procedure, the aortic arch, ascending aorta, descending aorta and left ventricle were delineated. Bland-Altman analyses were performed to assess the bias (mean difference) and variability (1.96 times the standard deviation of the differences) between IDBC and SDBC.

Results: Overall, the activity concentration obtained from the IDBC was lower than from the SDBC. When comparing IDBC with SDBC, variability was smallest for the ascending aorta (20.3% and 17.0% for ⁸⁹Zr-cetuximab and ⁸⁹Zr-durvalumab, respectively). Variability for the other regions ranged between 17.9 and 30.8%. Bias for the ascending aorta was - 10.9% and - 11.4% for ⁸⁹Zr-cetuximab and ⁸⁹Zr-durvalumab, respectively.

Conclusions: Image-derived blood concentrations should be obtained from delineating the ascending aorta in ⁸⁹Zr-immuno-PET scans, as this results in the lowest variability with respect to sample-derived blood concentrations.

查看原文本刊更多论文

如何从 89Zr-immuno-PET 扫描图像中获取血液浓度。

背景：使用锆-89 标记的单克隆抗体（89Zr-mAbs）进行 PET 扫描，即 89Zr-immuno-PET 扫描，是为了测量肿瘤和器官组织的摄取量。摄取量与血液中 89Zr-mAbs 的供应量有关。然而，测量血液中的活性浓度需要进行侵入性血液采样。本研究旨在确定从 89Zr-immuno-PET 扫描中获取图像衍生血液浓度（IDBC）的最佳划分策略：研究纳入了两种 89Zr-mAbs （89Zr-西妥昔单抗和 89Zr-durvalumab）的 PET 成像和血液采样。对接受 89Zr-cetuximab 治疗的七名患者注射后 1-2 h、2 天和 6 天的 PET 扫描结果进行了分析。五名患者接受了三次 89Zr-durvalumab 注射。前两次注射的扫描方案包括注射后 2 天、5 天和 7 天的 PET 扫描，第三次注射只在注射后 7 天进行。每次 PET 扫描都会抽取血液样本，样本衍生血液浓度（SDBC）被用作 IDBC 的金标准。根据内部制定的标准操作程序，对主动脉弓、升主动脉、降主动脉和左心室进行了划定。对 IDBC 和 SDBC 的偏差（平均差）和变异性（差值标准差的 1.96 倍）进行了 Bland-Altman 分析：总体而言，IDBC 的活性浓度低于 SDBC。比较 IDBC 和 SDBC，升主动脉的变异性最小（89Zr-西妥昔单抗和 89Zr-durvalumab 分别为 20.3% 和 17.0%）。其他区域的变异性介于 17.9% 和 30.8% 之间。89Zr-西妥昔单抗和89Zr-durvalumab的升主动脉偏差分别为-10.9%和-11.4%：结论：在89Zr-免疫PET扫描中，应通过划定升主动脉来获得图像衍生血液浓度，因为这与样本衍生血液浓度相比变异性最小。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

EJNMMI Physics Physics and Astronomy-Radiation

CiteScore

6.70

自引率

10.00%

发文量

审稿时长

13 weeks

期刊介绍： EJNMMI Physics is an international platform for scientists, users and adopters of nuclear medicine with a particular interest in physics matters. As a companion journal to the European Journal of Nuclear Medicine and Molecular Imaging, this journal has a multi-disciplinary approach and welcomes original materials and studies with a focus on applied physics and mathematics as well as imaging systems engineering and prototyping in nuclear medicine. This includes physics-driven approaches or algorithms supported by physics that foster early clinical adoption of nuclear medicine imaging and therapy.